Cargando…
Brain targeted drug delivery systems : a focus on nanotechnology and and nanoparticulates /
Brain Targeted Drug Delivery Systems: A Focus on Nanotechnology and Nanoparticulates provides a guide on nanoparticulates to both academic and industry researchers. The book discusses key points in the development of brain targeted drug delivery, summarizes available strategies, and considers the ma...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
London :
Academic Press,
©2019.
|
| Temas: | |
| Acceso en línea: | Texto completo |
Tabla de Contenidos:
- Front Cover; Brain Targeted Drug Delivery Systems: A Focus on Nanotechnology and Nanoparticulates; Copyright; Dedication; Contents; Contributors; Preface; Chapter 1: Introduction and overview; 1. Is it possible to deliver drugs to brain?; 2. What's the major concerns of brain-targeted DDS?; 3. Conclusion; Part I: Physiology and principles for brain targeting drug delivery; Chapter 2: Anatomy and physiology of blood-brain barrier; 1. Introduction; 2. Concept of blood-brain barrier; 3. Neurovascular unit; 3.1. Occludin; 3.2. Claudin; 3.3. Adhesion junctions; 3.4. Junctional adhesion molecules.
- 3.5. Accessory proteins3.6. Pericytes; 3.7. Neurons; 3.8. Extracellular matrix; 4. Role of astrocytes; 5. Transportation across blood-brain barrier; 6. Types of transport systems at blood-brain barrier; 6.1. Amino acid transport; 6.2. Hexose transport system; 6.3. Monocarboxylate transporter system; 6.4. Organic anion transporter family; 6.5. Organic cation transporter (OCT and OCTN) family; 6.6. Transport of nucleosides; 6.7. Transport of peptides; 6.8. Transport of macromolecules; 6.9. Transport of ions; 6.10. Transcytosis of macromolecules; 7. Conclusions; References.
- Chapter 3: Recent progress in blood-brain barrier transportation research1. Introduction; 2. Overview of the transport mechanisms at the BBB; 2.1. Carrier-mediated transcytosis; 2.1.1. Glucose transporters; 2.1.2. Large neutral amino acid transporter 1; 2.1.3. Monocarboxylate transporter 1; 2.2. Receptor-mediated transport; 2.2.1. Transferrin receptor; 2.2.2. Insulin receptor; 2.2.3. Low-density lipoprotein receptor-related protein; 2.3. Adsorptive-mediated transcytosis; 3. Strategies for improving CNS delivery of therapeutics; 3.1. Enhanced paracellular transport.
- 3.2. Improving physicochemical properties of CNS-active drugs3.3. Drug modification with targeting moieties; 3.4. Nanocarrier-based drug delivery; 3.5. Cell-based drug delivery; 4. Future perspectives; References; Chapter 4: In vitro and in vivo models of BBB to evaluate brain targeting drug delivery; 1. Introduction; 2. The neurovascular unit; 2.1. Endothelial cells; 2.2. Pericytes; 2.3. Astrocytes; 2.4. Molecular structure of the junction; 2.4.1. Tight junctions; 2.4.2. Adherens junction; 3. Movement through the blood-brain barrier; 3.1. Passive diffusion; 3.2. Carrier-mediated transport.
- 3.3. Active efflux pumps3.4. Transcytosis; 3.5. Cell-mediated transport; 4. In vitro models of BBB for assessing drug delivery; 4.1. Methods for measuring permeability; 4.1.1. TEER (trans-endothelial electric resistance) measurement; 4.1.2. FITC-dextran and sodium fluorescein; 4.1.3. Lucifer yellow; 4.1.4. Evans blue dye; 4.1.5. Horseradish peroxidase (HRP); 4.1.6. Mannitol/sucrose/inulin (radiolabeled); 4.2. In vitro models; 4.2.1. Noncell-based (synthetic) in vitro models; 4.2.1.1. Immobilized artificial membrane (IAM) chromatography; 4.2.1.2. Parallel artificial membrane permeability assay.